Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...
Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple ...
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results